{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:03:11Z","timestamp":1788404591020,"version":"build-2803163510"},"reference-count":19,"publisher":"Consilium Medicum","issue":"7","license":[{"start":{"date-parts":[[2017,7,15]],"date-time":"2017-07-15T00:00:00Z","timestamp":1500076800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>The aim of the present paper was to evaluate the clinical features and risk of thrombotic events (TE) in patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF), depending on the molecular characteristics of disease. Clinical data and laboratory parameters were analyzed in 50 ET patients and 50 PMF ones who had been followed up at the Department for Standardization of Treatments, National Research Center for Hematology, Ministry of Health of the Russian Federation, from February 2015 to September 2016. The patients with ET and those with PMF were found to have a high risk of TE. The risk for TE in the patients with ET is higher (24% in the entire group) than in those with PMF (14% in the study group). In ET, there is a high thrombosis risk in the detection of JAK2 and CALR gene mutations as compared with triple-negative cases. The PMF patients with JAK2 V617F mutations are at high risk for TE compared to those who are CALR mutation carriers and in triple-negative cases. There was no significant association of TE with high thrombocytosis. A factor, such as age, was found to be of no negative prognostic value in the patients with PMF.<\/jats:p>","DOI":"10.17116\/terarkh20178974-9","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T11:28:20Z","timestamp":1501673300000},"page":"4-9","source":"Crossref","is-referenced-by-count":4,"title":["Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease"],"prefix":"10.26442","volume":"89","author":[{"given":"A L","family":"Melikyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I N","family":"Subortseva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A B","family":"Sudarikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M","family":"Kovrigina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E A","family":"Gilyazitdinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T I","family":"Kolosheinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A O","family":"Abdullaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S A","family":"Treglazova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18344","published-online":{"date-parts":[[2017,7,15]]},"reference":[{"key":"ref1","unstructured":"\u041c\u0435\u043b\u0438\u043a\u044f\u043d \u0410.\u041b., \u0422\u0443\u0440\u043a\u0438\u043d\u0430 \u0410.\u0413., \u0410\u0431\u0434\u0443\u043b\u043a\u0430\u0434\u044b\u0440\u043e\u0432 \u041a.\u041c., \u0417\u0430\u0440\u0438\u0446\u043a\u0438\u0439 \u0410.\u042e., \u0410\u0444\u0430\u043d\u0430\u0441\u044c\u0435\u0432 \u0411.\u0412., \u0428\u0443\u0432\u0430\u0435\u0432 \u0412.\u0410., \u041b\u043e\u043c\u0430\u0438\u0430 \u0415.\u0413., \u041c\u043e\u0440\u043e\u0437\u043e\u0432\u0430 \u0415.\u0412., \u0411\u0430\u0439\u043a\u043e\u0432 \u0412.\u0412., \u0413\u043e\u043b\u0435\u043d\u043a\u043e\u0432 \u0410.\u041a., \u0421\u0443\u0431\u043e\u0440\u0446\u0435\u0432\u0430 \u0418.\u041d., \u0421\u043e\u043a\u043e\u043b\u043e\u0432\u0430 \u041c.\u0410., \u041a\u043e\u0432\u0440\u0438\u0433\u0438\u043d\u0430 \u0410.\u041c., \u041c\u0430\u0440\u0442\u044b\u043d\u043a\u0435\u0432\u0438\u0447 \u0418.\u0421., \u0413\u0440\u0438\u0446\u0430\u0435\u0432 \u0421.\u0412., \u0421\u0443\u0434\u0430\u0440\u0438\u043a\u043e\u0432 \u0410.\u0411., \u0421\u0443\u0445\u0430\u043d\u043e\u0432\u0430 \u0413.\u0410., \u0418\u0432\u0430\u043d\u043e\u0432\u0430 \u0412.\u041b., \u041a\u0430\u043f\u043b\u0430\u043d\u043e\u0432 \u041a.\u0414., \u041a\u043e\u043d\u0441\u0442\u0430\u043d\u0442\u0438\u043d\u043e\u0432\u0430 \u0422.\u0421., \u041f\u043e\u0441\u043f\u0435\u043b\u043e\u0432\u0430 \u0422.\u0418., \u0410\u0433\u0435\u0435\u0432\u0430 \u0422.\u0410., \u0428\u0430\u0442\u043e\u0445\u0438\u043d \u042e.\u0412., \u0421\u0430\u0432\u0447\u0435\u043d\u043a\u043e \u0412.\u0413. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 \u043f\u043e \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0435 \u0438 \u0442\u0435\u0440\u0430\u043f\u0438\u0438 Ph-\u043d\u0435\u0433\u0430\u0442\u0438\u0432\u043d\u044b\u0445 \u043c\u0438\u0435\u043b\u043e\u043f\u0440\u043e\u043b\u0438\u0444\u0435\u0440\u0430\u0442\u0438\u0432\u043d\u044b\u0445 \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u0439 (\u0438\u0441\u0442\u0438\u043d\u043d\u0430\u044f \u043f\u043e\u043b\u0438\u0446\u0438\u0442\u0435\u043c\u0438\u044f, \u044d\u0441\u0441\u0435\u043d\u0446\u0438\u0430\u043b\u044c\u043d\u0430\u044f \u0442\u0440\u043e\u043c\u0431\u043e\u0446\u0438\u0442\u0435\u043c\u0438\u044f, \u043f\u0435\u0440\u0432\u0438\u0447\u043d\u044b\u0439 \u043c\u0438\u0435\u043b\u043e\u0444\u0438\u0431\u0440\u043e\u0437). \u0413\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f \u0438 \u0442\u0440\u0430\u043d\u0441\u0444\u0443\u0437\u0438\u043e\u043b\u043e\u0433\u0438\u044f. 2014;59(4):31-56."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"\u041c\u0435\u043b\u0438\u043a\u044f\u043d \u0410.\u041b., \u0421\u0443\u0431\u043e\u0440\u0446\u0435\u0432\u0430 \u0418.\u041d. \u0411\u0438\u043e\u043b\u043e\u0433\u0438\u044f \u043c\u0438\u0435\u043b\u043e\u043f\u0440\u043e\u043b\u0438\u0444\u0435\u0440\u0430\u0442\u0438\u0432\u043d\u044b\u0445 \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u0439. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u043e\u043d\u043a\u043e\u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f. 2016; 9(3):314-325.","DOI":"10.21320\/2500-2139-2016-9-3-314-325"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007;21(9): 1960-1963. https:\/\/doi.org\/10.1038\/sj.leu.2404810","DOI":"10.1038\/sj.leu.2404810"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: A critical reappraisal. Leukemia. 2008;22(7):1299-1307. https:\/\/doi.org\/10.1038\/leu.2008.113","DOI":"10.1038\/leu.2008.113"},{"key":"ref5","unstructured":"\u0422\u0440\u0435\u0433\u043b\u0430\u0437\u043e\u0432\u0430 \u0421.\u0410., \u0410\u0431\u0434\u0443\u043b\u043b\u0430\u0435\u0432 \u0410.\u041e., \u041c\u0430\u043a\u0430\u0440\u0438\u043a \u0422.\u0412., \u0421\u0443\u0431\u043e\u0440\u0446\u0435\u0432\u0430 \u0418.\u041d., \u041c\u0435\u043b\u0438\u043a\u044f\u043d \u0410.\u041b., \u0421\u0443\u0434\u0430\u0440\u0438\u043a\u043e\u0432 \u0410.\u0411. \u0418\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u0435 \u043c\u0443\u0442\u0430\u0446\u0438\u0439 JAK2V617F, MPL W515L\/K \u0438 9 \u044d\u043a\u0437\u043e\u043d\u0430 \u0433\u0435\u043d\u0430 CALR \u0443 \u043f\u0430\u0446\u0438\u0435\u043d\u0442\u043e\u0432 \u0441 \u044d\u0441\u0441\u0435\u043d\u0446\u0438\u0430\u043b\u044c\u043d\u043e\u0439 \u0442\u0440\u043e\u043c\u0431\u043e\u0446\u0438\u0442\u0435\u043c\u0438\u0435\u0439. \u0413\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f \u0438 \u0442\u0440\u0430\u043d\u0441\u0444\u0443\u0437\u0438\u043e\u043b\u043e\u0433\u0438\u044f. 2016;61(1):74."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Tefferi A, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-1097 https:\/\/doi.org\/10.1182\/blood-2007-04-083501","DOI":"10.1182\/blood-2007-04-083501"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2V617F mutation status: a prospective study. The Lancet. 2005. 366(9501);1945-1953. https:\/\/doi.org\/10.1016\/S0140-6736(05)67785-9","DOI":"10.1016\/S0140-6736(05)67785-9"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Pardanani A, Lasho TL, Finke CM, Tefferi A. Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis. Am J Hematol. 2011;86(8):701-702. https:\/\/doi.org\/10.1002\/ajh.22058","DOI":"10.1002\/ajh.22058"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Ohashi H, Arita K, Fukami S, Oguri K, Nagai H, Yokozawa T, Hotta T, Hanada S. Two rare MPL gene mutations in patients with essential thrombocythemia. Int J Hematol. 2009;90(3):431-432. https:\/\/doi.org\/10.1007\/s12185-009-0413-3","DOI":"10.1007\/s12185-009-0413-3"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Beer PA, Campbell PJ, Bench AJ, Erber WN, Bareford D, Wilkins BS, Reilly JT, Hasselbalch HC, Bowman R, Wheatley K, Buck G, Harrison CN, Green AR. MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort. Blood. 2008;112(1):141-149. https:\/\/doi.org\/10.1182\/blood-2008-01-131664","DOI":"10.1182\/blood-2008-01-131664"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A, Tsuboi K, Nitta M, Miyazaki H, Iida S, Ueda R. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103(11):4198-4200. https:\/\/doi.org\/10.1182\/blood-2003-10-3471","DOI":"10.1182\/blood-2003-10-3471"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Liu K, Martini M, Rocca B, Amos CI, Teofili L, Giona F, Ding J, Komatsu H, Larocca LM, Skoda RC. Evidence for a founder effect of the MPLS505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica. 2009;94(10):1368-1374. https:\/\/doi.org\/10.3324\/haematol.2009.005918.","DOI":"10.3324\/haematol.2009.005918"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O\u2019Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJ, Harrison CN, Cross NC, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR. Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2. N Engl J Med. 2013;369(25):2391-405. https:\/\/doi.org\/10.1056\/NEJMoa1312542","DOI":"10.1056\/NEJMoa1312542"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NCC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer G I, Bagienski K, Milanesi C, Carola Casetti I, Sant\u2019Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Sch\u00f6negger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369(25):2379-2390. https:\/\/doi.org\/10.1056\/NEJMoa1311347","DOI":"10.1056\/NEJMoa1311347"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, Roncoroni E, Astori C, Merli M, Boggi S, Pascutto C, Lazzarino M, Cazzola M. A prospective study of 338 patients with polycythemia vera: The impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24(9):1574-1579. https:\/\/doi.org\/10.1038\/leu.2010.148","DOI":"10.1038\/leu.2010.148"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122(13):2176-2184 https:\/\/doi.org\/10.1182\/blood-2013-03-460154","DOI":"10.1182\/blood-2013-03-460154"},{"key":"ref17","unstructured":"\u041c\u0435\u043b\u0438\u043a\u044f\u043d \u0410.\u041b., \u0421\u0443\u0431\u043e\u0440\u0446\u0435\u0432\u0430 \u0418.\u041d. \u041c\u0430\u0442\u0435\u0440\u0438\u0430\u043b\u044b 56-\u0433\u043e \u043a\u043e\u043d\u0433\u0440\u0435\u0441\u0441\u0430 \u0410\u043c\u0435\u0440\u0438\u043a\u0430\u043d\u0441\u043a\u043e\u0433\u043e \u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u043e\u0431\u0449\u0435\u0441\u0442\u0432\u0430 (\u0434\u0435\u043a\u0430\u0431\u0440\u044c 2014 \u0433., \u0421\u0430\u043d-\u0424\u0440\u0430\u043d\u0446\u0438\u0441\u043a\u043e). \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u043e\u043d\u043a\u043e\u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f. \u0424\u0443\u043d\u0434\u0430\u043c\u0435\u043d\u0442\u0430\u043b\u044c\u043d\u044b\u0435 \u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u044f \u0438 \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u043f\u0440\u0430\u043a\u0442\u0438\u043a\u0430. 2015; 8(2):201-232."},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012; 120(26):5128-5133. https:\/\/doi.org\/10.1182\/blood-2012-07-444067","DOI":"10.1182\/blood-2012-07-444067"},{"key":"ref19","unstructured":"\u041c\u0435\u043b\u0438\u043a\u044f\u043d \u0410.\u041b., \u0421\u0443\u0431\u043e\u0440\u0446\u0435\u0432\u0430 \u0418.\u041d. \u041c\u0430\u0442\u0435\u0440\u0438\u0430\u043b\u044b 19-\u0433\u043e \u043a\u043e\u043d\u0433\u0440\u0435\u0441\u0441\u0430 \u0415\u0432\u0440\u043e\u043f\u0435\u0439\u0441\u043a\u043e\u0439 \u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u0430\u0441\u0441\u043e\u0446\u0438\u0430\u0446\u0438\u0438 (2014 \u0433., \u041c\u0438\u043b\u0430\u043d). \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u043e\u043d\u043a\u043e\u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f. \u0424\u0443\u043d\u0434\u0430\u043c\u0435\u043d\u0442\u0430\u043b\u044c\u043d\u044b\u0435 \u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u044f \u0438 \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u043f\u0440\u0430\u043a\u0442\u0438\u043a\u0430. 2014;7(4):598-607."}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/32255\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/32255\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T22:23:32Z","timestamp":1634077412000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/32255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,15]]},"references-count":19,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7,15]]}},"URL":"https:\/\/doi.org\/10.17116\/terarkh20178974-9","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"value":"2309-5342","type":"electronic"},{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7,15]]}}}